What causes behavioral side effects in popular weight loss drugs?
GLP1R gene variants link to cardiometabolic traits and behavioral changes, but findings suggest behavioral effects of GLP1RA are indirect Study: ...
Tag: Glucagon-like Peptide-1
Benefits and risks of popular weight-loss drugs revealed
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...
Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication
Anti-obesity medications linked to reduced alcohol use, possibly due to effects on cravings and reward systems, with behavioral strategies also ...
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder
A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential ...
GLP-1 receptor agonists show promise in treating substance use disorders
A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due ...
Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation
Study: Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. Image Credit: myskin / Shutterstock.com In a recent ...
Sustainable weight loss with personalized semaglutide dosing
New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has explored the benefits ...
Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity
In a recent study published in Scientific Reports, researchers evaluated the impact of semaglutide and tirzepatide medications on alcohol consumption ...
